NCT07034703View on ClinicalTrials.gov

Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial

Not yet recruitingOBSERVATIONAL
Enrollment

820

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2030

Study Completion Date

January 31, 2032

Conditions
Resectable Pancreatic Duct Adenocarcinoma
Trial Locations (1)

76031

CHU de Rouen, Rouen

All Listed Sponsors
collaborator

Federation of Research in Surgery (FRENCH)

OTHER

lead

University Hospital, Rouen

OTHER